How does immune globulin therapy work? Now is the time to find out

November 21, 2012

Immune globulin replacement began decades ago as a treatment for patients who could not make their own protective antibodies, but has proven to have much broader benefits than originally expected. With new uses regularly being discovered for this limited and expensive resource, including as a potential treatment for Alzheimer's disease, now is the time to discover exactly how intravenous immune globulin (IVIG) treatments work, and to engineer a protein that can provide similar benefits, writes Erwin Gelfand, MD, chair of pediatrics at National Jewish Health in the November 22, 2012, issue of the New England Journal of Medicine.

"It has been a challenge to understand exactly how IVIG provides its antiinflammatory and immunomodulatory benefits," said Dr. Gelfand. "We need to figure it out so we can bring this treatment to more people who have no other options for treating their conditions."

Dr. Gelfand is an internationally recognized expert on immune deficiencies. In the late 1960s he was among the first to successfully perform a bone-marrow transplant for severe combined immune deficiency. He has used IVIG for decades to treat patients with inflammatory and .

solutions are prepared from the pooled plasma of thousands of healthy . Thus, it carries a tremendous diversity of antibodies, which can help defend against a wide variety of pathogens. It was originally introduced in the 1950s as a treatment to replace the missing disease-fighting antibodies in patients whose left them vulnerable to infections.

Fairly quickly, however, it became apparent that its benefits extended beyond simple antibody replacement. In a patient with an autoimmune blood disease, it successfully restored blood platelet numbers, cells that help clot blood. Since then dozens of immune and have been shown to benefit from IVIG treatment, including Kawasaki's disease, , Guillain-Barré syndrome, myasthenia gravis, graft-versus-host disease and chronic lymphocytic leukemia.

Dr. Gelfand and others believe that there are probably several mechanisms responsible for the benefits of IVIG. While antibodies have a primary binding site that they use to detect and clear hazardous proteins, they also have several other binding sites that interact with cells and soluble proteins that influence inflammatory and immune processes. IVIG also contains soluble proteins, including cytokines and chemokines, that could contribute to its beneficial effects.

While some progress has been made in understanding the beneficial mechanisms of IVIG, no definitive proteins have been discovered that could serve as substitute treatments.

"With a growing list of diseases that respond to IVIG treatments and its potential use for Alzheimer's disease, demand for IVIG will soon outstrip our ability to collect and provide it to patients in need," said Dr. Gelfand. "Now is the time to accelerate and focus our efforts on understanding IVIG's extraordinary actions."

Explore further: Guideline: IVIg effective for certain nerve and muscle disorders

Related Stories

Guideline: IVIg effective for certain nerve and muscle disorders

March 26, 2012
Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating ...

Better and more affordable treatments for sufferers of autoimmune diseases

December 13, 2011
(Medical Xpress) -- From Addison’s disease to Rheumatoid Arthritis, Crohn’s disease to Multiple Sclerosis — the list of crippling autoimmune diseases is long and they affect millions of people world-wide. But ...

Costly treatment 'ineffective for babies'

September 30, 2011
(Medical Xpress) -- A worldwide study involving University of Sydney researchers has concluded that a costly and controversial treatment for neonatal sepsis is ineffective.

Recommended for you

Genetic immune deficiency could hold key to severe childhood infections

July 18, 2017
A gene mutation making young children extremely vulnerable to common viruses may represent a new type of immunodeficiency, according to a University of Queensland researcher.

What are the best ways to diagnose and manage asthma?

July 18, 2017
What are the best ways to diagnose and manage asthma in adults? This can be tricky because asthma can stem from several causes and treatment often depends on what is triggering the asthma.

Large multi-ethnic study identifies many new genetic markers for lupus

July 17, 2017
Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus.

Study finds molecular explanation for struggles of obese asthmatics

July 17, 2017
A large, bouquet-shaped molecule called surfactant protein A, or SP-A, may explain why obese asthma patients have harder-to-treat symptoms than their lean and overweight counterparts, according to a new study led by scientists ...

Team identifies potential cause for lupus

July 14, 2017
Leading rheumatologist and Feinstein Institute for Medical Research Professor Betty Diamond, MD, may have identified a protein as a cause for the adverse reaction of the immune system in patients suffering from lupus. A better ...

Immunosuppression underlies resistance to anti-angiogenic therapy

July 14, 2017
A Massachusetts General Hospital (MGH) research team has identified a novel mechanism behind resistance to angiogenesis inhibitors - drugs that fight cancer by suppressing the formation of new blood vessels. In their report ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.